ARK Investment Management LLC Acquires 252,029 Shares of Juno Therapeutics, Inc. (JUNO)

ARK Investment Management LLC lifted its holdings in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 101.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 500,296 shares of the biopharmaceutical company’s stock after purchasing an additional 252,029 shares during the quarter. Juno Therapeutics comprises about 2.9% of ARK Investment Management LLC’s holdings, making the stock its 8th biggest holding. ARK Investment Management LLC owned about 0.48% of Juno Therapeutics worth $14,954,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. Utah Retirement Systems lifted its position in shares of Juno Therapeutics by 1.8% during the second quarter. Utah Retirement Systems now owns 11,600 shares of the biopharmaceutical company’s stock worth $347,000 after purchasing an additional 200 shares in the last quarter. State of Wisconsin Investment Board lifted its position in shares of Juno Therapeutics by 1.7% during the second quarter. State of Wisconsin Investment Board now owns 12,562 shares of the biopharmaceutical company’s stock worth $375,000 after purchasing an additional 210 shares in the last quarter. Amalgamated Bank lifted its position in shares of Juno Therapeutics by 19.0% during the second quarter. Amalgamated Bank now owns 10,900 shares of the biopharmaceutical company’s stock worth $326,000 after purchasing an additional 1,741 shares in the last quarter. Creative Planning lifted its position in shares of Juno Therapeutics by 5.9% during the second quarter. Creative Planning now owns 50,827 shares of the biopharmaceutical company’s stock worth $1,519,000 after purchasing an additional 2,811 shares in the last quarter. Finally, Aperio Group LLC lifted its position in shares of Juno Therapeutics by 11.9% during the second quarter. Aperio Group LLC now owns 28,360 shares of the biopharmaceutical company’s stock worth $848,000 after purchasing an additional 3,024 shares in the last quarter. 70.76% of the stock is currently owned by institutional investors and hedge funds.

Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) traded up 9.8027% during mid-day trading on Friday, reaching $45.6999. 4,494,885 shares of the company traded hands. The firm’s 50 day moving average price is $34.94 and its 200-day moving average price is $27.48. The company’s market capitalization is $4.79 billion. Juno Therapeutics, Inc. has a 52-week low of $17.52 and a 52-week high of $47.00.

Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.24). Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The company had revenue of $21.30 million for the quarter, compared to analyst estimates of $15.59 million. During the same period last year, the firm posted ($0.64) earnings per share. The business’s revenue was down 22.8% on a year-over-year basis. Equities analysts predict that Juno Therapeutics, Inc. will post ($3.12) earnings per share for the current fiscal year.

JUNO has been the topic of several research reports. Wedbush raised shares of Juno Therapeutics from a “neutral” rating to an “outperform” rating and set a $42.00 price target on the stock in a research report on Tuesday, August 29th. Wells Fargo & Company reissued an “outperform” rating and set a $54.00 price target (up previously from $35.00) on shares of Juno Therapeutics in a research report on Tuesday, September 5th. Raymond James Financial, Inc. raised shares of Juno Therapeutics from a “market perform” rating to an “outperform” rating and set a $45.00 price target on the stock in a research report on Tuesday, August 29th. Standpoint Research reissued a “reduce” rating on shares of Juno Therapeutics in a research report on Thursday, August 31st. Finally, Vetr raised shares of Juno Therapeutics from a “sell” rating to a “hold” rating and set a $28.85 price target on the stock in a research report on Monday, July 10th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the stock. Juno Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $34.88.

COPYRIGHT VIOLATION NOTICE: “ARK Investment Management LLC Acquires 252,029 Shares of Juno Therapeutics, Inc. (JUNO)” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://ledgergazette.com/2017/09/22/ark-investment-management-llc-acquires-252029-shares-of-juno-therapeutics-inc-juno.html.

In other Juno Therapeutics news, major shareholder Douglas K. Bratton sold 8,000,000 shares of the company’s stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $27.00, for a total value of $216,000,000.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Steve Harr sold 8,750 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $30.00, for a total value of $262,500.00. Following the completion of the transaction, the chief financial officer now directly owns 736,189 shares in the company, valued at $22,085,670. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,119,219 shares of company stock worth $220,455,844. 15.26% of the stock is currently owned by corporate insiders.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Want to see what other hedge funds are holding JUNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juno Therapeutics, Inc. (NASDAQ:JUNO).

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply